Table 3.
Trends in meningioma incidence rates (2004‐2015): The SEER‐18 registry database
| Characteristic | Overall (2004‐2015) | Trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | |||||||||
| APC (95% CI) | P | Year | APC (95% CI) | P | Year | APC (95% CI) | P | Year | APC (95% CI) | P | |
| Overall | 1.9 (1.0 to 2.7) | ＜.001 | 2004‐2009 | 4.6 (3.4 to 5.9) | ＜.001 | 2009‐2015 | 0 (−0.8 to 0.8) | .969 | |||
| Sex | |||||||||||
| Male | 1.8 (0.9 to 2.7) | .001 | 2004‐2009 | 4.7 (3.2 to 6.1) | ＜.001 | 2009‐2015 | ‐0.2 (−1.1 to 0.8) | .679 | |||
| Female | 2.0 (1.1 to 2.8) | ＜.001 | 2004‐2009 | 4.6 (3.2 to 6.1) | ＜.001 | 2009‐2015 | 0.2 (−0.8 to 1.1) | .688 | |||
| Race | |||||||||||
| White | 2.0 (1.2 to 2.9) | ＜.001 | 2004‐2009 | 4.6 (3.2 to 6.1) | ＜.001 | 2009‐2015 | 0.2 (−0.7 to 1.2) | .589 | |||
| Black | 1.1 (−0.1 to 2.4) | .070 | 2004‐2010 | 4.3 (3.3 to 5.2) | ＜.001 | 2010‐2015 | ‐2.3 (−3.4 to −1.3) | .001 | |||
| AIANa | 2.7 (−1.1 to 6.7) | .150 | |||||||||
| APIa | 0.4 (−0.5 to 1.3) | .402 | |||||||||
| Age at diagnosis | |||||||||||
| <20a | 3.6 (0.5 to 6.9) | .029 | |||||||||
| 20‐39a | 2.5 (1.8 to 3.3) | ＜.001 | |||||||||
| 40‐59a | 1.8 (1.3 to 2.4) | ＜.001 | |||||||||
| 60‐79 | 1.5 (0.5 to 2.5) | .008 | 2004‐2009 | 4.8 (3.0 to 6.6) | ＜.001 | 2009‐2015 | ‐0.7 (−1.8 to 0.5) | .207 | |||
| ≥80 | 2.4 (1.0 to 3.8) | .004 | 2004‐2009 | 7.0 (4.9 to 9.1) | ＜.001 | 2009‐2015 | ‐0.6 (−1.9 to 0.7) | .289 | |||
| Histologic type | |||||||||||
| Meningioma, NOS | 2.5 (1.5 to 3.4) | ＜.001 | 2004‐2009 | 5.5 (4.0 to 7.0) | ＜.001 | 2009‐2015 | 0.5 (−0.5 to 1.4) | .280 | |||
| Meningotheliala | −1.3 (−2.5 to −0.1) | .041 | |||||||||
| Fibrous | −5.8 (−7.6 to −3.9) | ＜.001 | 2004‐2012 | −3.7 (−5.7 to −1.6) | .004 | 2012‐2015 | −15.7 (−25.6 to −4.3) | .015 | |||
| Psammomatousa | −2.4 (−5.0 to 0.3) | .080 | |||||||||
| Angiomatousa | −1.4 （−4.2 to 1.4） | .286 | |||||||||
| Transitionala | −5.0 (−6.9 to −3.0) | ＜.001 | |||||||||
| Clear cella | 3.0 (0.2 to 5.9) | .040 | |||||||||
| Atypicala | 4.0 (3.0 to 5.0) | ＜.001 | |||||||||
| WHO grade | |||||||||||
| I | 1.9 (1.0 to 2.8) | ＜.001 | 2004‐2009 | 4.9 (3.5 to 6.3) | ＜.001 | 2009‐2015 | −0.1 (−1.0 to 0.8) | .799 | |||
| II | 2.8 (1.8 to 3.9) | ＜.001 | 2004‐2008 | 7.1 (3.8 to 10.6) | .004 | 2008‐2011 | ‐2.6 (−11.2 to 6.8) | .471 | 2011‐2015 | 5.4 (2.6 to 8.3) | .006 |
| IIIa | −5.6 (−8.5 to −2.6) | .002 | |||||||||
| Tumor size, cm | |||||||||||
| ≤3 | 4.9 (3.3 to 6.6) | ＜.001 | 2004‐2009 | 10.6 (8.2 to 13.1) | ＜.001 | 2009‐2015 | 1.6 (0.2 to 2.9) | .027 | |||
| >3 to ≤5 | 2.5 (1.4 to 3.7) | ＜.001 | 2004‐2009 | 5.9 (3.0 to 8.9) | .002 | 2009‐2015 | 0.3 (−1.5 to 2.2) | .682 | |||
| >5a | 3.2 (1.9 to 4.5) | ＜.001 | |||||||||
| Unknowna | −7.5 (−8.9 to −6.0) | ＜.001 | |||||||||
Abbreviations: AIAN, American Indian/Alaskan Native; APC, annual percent change; API, Asian/Pacific Islander; SEER, Surveillance, Epidemiology, and End Results.
Note Each time period is determined by Joinpoint Program when a statistically significant change in the APC occurred.
a
Denotes only an overall trend for this subgroup after joinpoint analysis.